Angiotensin II for the treatment of high-output shock 3 (ATHOS-3): Protocol for a phase III, double-blind, randomised controlled trial

Critical Care and Resuscitation

Volumn 19, Issue 1, 2017, Pages 43-49

  Chawla, Lakhmir S ^a,b   Russell, James A ^c   Bagshaw, Sean M ^d   Shaw, Andrew D ^e   Goldstein, Stuart L ^f   Fink, Mitchell P ^g   Tidmarsh, George F ^b,h  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b La Jolla Pharmaceutical Company   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; VASOCONSTRICTOR AGENT;

CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HYPOTENSION; METHODOLOGY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN II; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; HUMANS; HYPOTENSION; RESEARCH DESIGN; VASOCONSTRICTOR AGENTS;

EID: 85013791046     PISSN: 14412772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 801-10.
2. Duan C, Yang G, Li T, Liu L. Advances in vascular hyporeactivity after shock: the mechanisms and managements. Shock 2015; 44: 524-34.
3. Bassi E, Park M, Azevedo LCP. Therapeutic strategies for high-dose vasopressor-dependent shock. Crit Care Res Pract 2013; 2013: 654708.
4. Karnik SS, Unal H, Kemp JR, et al. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli [corrected]. Pharmacol Rev 2015; 67: 754-819.
5. Whiteley SM, Dade JP. Treatment of hypotension in septic shock. Lancet 1996; 347: 622.
6. Thomas VL, Nielsen MA. Administration of angiotensin II in refractory septic shock. Crit Care Med 1991; 19: 1084-6.
7. Ryding J, Heslet L, Hartvig T, Jønsson V. Reversal of ‘refractory septic shock’ by infusion of amrinone and angiotensin II in an anthracycline-treated patient. Chest 1995; 107: 201-3.
8. Cohn JN, Luria MH. Studies in clinical shock and hypotension. II. Hemodynamic effects of norepinephrine and angiotensin. J Clin Invest 1965; 44: 1494-504.
9. Wray GM, Coakley JH. Severe septic shock unresponsive to noradrenaline. Lancet 1995; 346: 1604.
10. Chawla LS, Busse LW, Brasha-Mitchell E, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS Trial): a pilot study. Crit Care 2014; 18: 534.
11. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358: 877-87.
12. Overgaard CB, Džavík V. Inotropes and vasopressors. Circulation 2008; 118: 1047-56.
13. Kaukonen KM, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014; 311: 1308-16.
14. Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med 2001; 29: 1860-7.
15. Park TK, Yang JH, Jeon K, et al. Extracorporeal membrane oxygenation for refractory septic shock in adults. Eur J Cardiothorac Surg 2015; 47: e68-74.
16. Ratanarat R, Brendolan A, Piccinni P, et al. Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival. Crit Care 2005; 9: R294-302.
17. Zhang W, Chen X, Huang L, et al. Severe sepsis: low expression of the renin-angiotensin system is associated with poor prognosis. Exp Ther Med 2014; 7: 1342-8.
18. Dial S, Nessim SJ, Kezouh A, et al. Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis. Br J Clin Pharmacol 2014; 78: 1151-8.
19. Nakada TA, Russell JA, Boyd JH, et al. Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock. Crit Care Med 2011; 39: 1641-8.
20. Kay ES, Batey DS, Mugavero MJ. The HIV treatment cascade and care continuum: updates, goals, and recommendations for the future. AIDS Res Ther 2016; 13: 35.
21. Coates LC, FitzGerald O, Helliwell PS, Paul C. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same? Semin Arthritis Rheum 2016; Jun 2. doi: 10.1016/j.semarthrit.2016.05.012 [Epub ahead of print].
22. Braam B, Taler SJ, Rahman M, et al. Recognition and management of resistant hypertension. Clin J Am Soc Nephrol 2016; Nov 28 [Epub ahead of print].